A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
Seo‐Young Park, M.-H. Lee, Minjung Seong, S.T. Kim, Jin Hyoung Kang, Byoung Chul Cho, K.H. Lee, E.K. Cho, Jong‐Mu Sun, S.-H. Lee, Jin Seok Ahn, K. Park, Myung‐Ju Ahn
Topics & Concepts
MedicineOsimertinibT790MInternal medicineOncologyLung cancerBrain metastasisCohortEpidermal growth factor receptorPhases of clinical researchCancerMetastasisChemotherapyErlotinibGefitinibLung Cancer Treatments and MutationsBrain Metastases and TreatmentLung Cancer Research Studies